$MACK Headlines Merrimack Pharma shares surge on

New Post Public Reply Private Reply Replies (0) Message Board

Sep 30, 2014 at 11:49 AM

$MACK Headlines

Merrimack Pharma shares surge on licensing pact with Baxter 7:54 a.m. Sept. 24, 2014 - Tomi Kilgore
Stock futures rise on Bernanke rate comments 5:46 p.m. July 10, 2013 - Wallace Witkowski
Merrimack to offer $50 mln in stock, $75 mln notes 5:24 p.m. July 10, 2013 - MarketWatch.com
Stocks to watch Friday: Goldman, Bally, Scotts 6:54 a.m. Aug. 10, 2012 - MarketWatch
IPO scorecard: Update on selected offering 2:18 p.m. June 8, 2012 - Dow Jones
Shares of Merrimack Pharmaceuticals off post IPO 3:19 a.m. March 30, 2012 - MarketWatch.com

Merrimack Pharmaceuticals (MACK) Strong On High Relative Volume Today 10:01 a.m. Today - TheStreet.com
How Merrimack Pharmaceuticals (MACK) Stock Stands Out in a Strong Industry - Tale of the Tape 8:36 a.m. Sept. 29, 2014 - Zacks.com
Will Merrimack (MACK) Continue to Surge Higher? - Tale of the Tape 10:09 a.m. Sept. 26, 2014 - Zacks.com
Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session - Tale of the Tape 9:39 a.m. Sept. 26, 2014 - Zacks.com
Baxter and Merrimack Collaborate on Drug Development - Analyst Blog 1:10 p.m. Sept. 25, 2014 - Zacks.com
Update: Merrimack Licenses MM-398 - Value Potential Dramatically Improves 11:30 a.m. Sept. 24, 2014 - Seeking Alpha
Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today 10:30 a.m. Sept. 24, 2014 - TheStreet.com
Merrimack Does Well to License Marginal Cancer Drug to Baxter 8:14 a.m. Sept. 24, 2014 - TheStreet.com
Merrimack Pharmaceuticals (MACK): Heavy Pre-Market Activity 8:10 a.m. Sept. 24, 2014 - TheStreet.com
Baxter, Merrimack to Collaborate on Pancreatic Cancer Drug 7:43 a.m. Sept. 24, 2014 - The Wall Street Journal Interactive Edition
Baxter and Merrimack collaborate on cancer drug 7:34 a.m. Sept. 24, 2014 - Seeking Alpha
Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? - Tale of the Tape 8:39 a.m. Sept. 10, 2014 - Zacks.com
Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape 8:43 a.m. Sept. 9, 2014 - Zacks.com
Will Merrimack Pharmaceuticals (MACK) Crush Estimates at Its Next Earnings Report? - Tale of the Tape 8:54 a.m. Aug. 20, 2014 - Zacks.com
10-Q: MERRIMACK PHARMACEUTICALS INC 4:05 p.m. Aug. 11, 2014 - Edgar Online - (EDG = 10Q, 10K)
Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q2 2014 Results - Earnings Call Transcript 3:01 p.m. Aug. 11, 2014 - Seeking Alpha
Update: Merrimack Earnings - Looming Concerns Still Remain 2:04 p.m. Aug. 11, 2014 - Seeking Alpha
More on Merrimack Pharma Q2 results 8:02 a.m. Aug. 11, 2014 - Seeking Alpha
Is Now The Time To Buy Merrimack Pharmaceuticals? 11:17 a.m. July 8, 2014 - Seeking Alpha
They're the Millers: Two Best Funds in Winners' Circle Contest 4:47 p.m. July 6, 2014 - The Wall Street Journal Interactive Edition

Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer 8:00 a.m. Today - GlobeNewswire
PharmaEngine and Merrimack Amend MM-398 License Agreement 4:58 a.m. Sept. 26, 2014 - BusinessWire - BZX
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 7:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress 8:00 a.m. Sept. 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval 7:06 a.m. Aug. 11, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results 7:01 a.m. Aug. 11, 2014 - GlobeNewswire
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax 8:50 a.m. Aug. 7, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call 4:02 p.m. Aug. 4, 2014 - GlobeNewswire
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 6:40 a.m. June 27, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 4:05 p.m. June 25, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 8:15 a.m. June 25, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121 4:15 p.m. June 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 8:01 a.m. June 17, 2014 - GlobeNewswire
Battle of the Biotech Bands - A Great Time for a Great Cause 2:45 p.m. June 12, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting 4:00 p.m. June 2, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers 9:36 a.m. June 2, 2014 - GlobeNewswire
Fundraising Support, Upcoming Conferences, Clinical Data Presentations, and Cash Dividends - Analyst Notes on WellCare, NPS Pharma, Merrimack Pharmaceuticals, CONMED and Haemonetics 8:00 a.m. May 28, 2014 - PR Newswire - PRF
Equities Marking a New High -- Research on JD.com, NRG Energy, Merrimack Pharma and Arris Group 5:40 a.m. May 28, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference 8:01 a.m. May 27, 2014 - GlobeNewswire
Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014 5:25 p.m. May 22, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Faces Class Action: Investors Seek Justice

When you hear a heavyweight like D-Wave Quantum Inc. finding itself tangled in a securities fraud lawsuit, you know there’s something big brewing. D-Wave Quantum Inc. NASDAQ: QBTS is under the spotlight and the clock is ticking. If you've dipped your toes into their stock between February 26, 2026, and August 25, 2026, chances are, this might be your ticket to seek some...

Noma Hits Fortune Cyber 60 with AI Security Success

Celebrating an AI Security Standout Well, look at that, Noma's found itself on the Fortune Cyber 60 list for 2026-2027. This listing isn't just some vanity metric. We’re talking about getting the nod from heavyweights like Lightspeed Venture Partners and Amazon Web Services. It recognizes them among 60 pivotal, venture-backed cybersecurity players, and sure, it’s in...

Fashion Sees Quality Trumping Price in Consumer Preferences

Consumers Are Shifting Away from Price-First Mindset You could always count on shoppers looking for a bargain, right? Well, hold your horses, 'cause that train's rolling off the tracks. In today's fashion shuffle, good ol' quality and craftsmanship are giving low prices a run for their money. A study spearheaded by Boston Consulting Group (BCG) and Women's Wear Daily...

Bugsy Siegel's Cold Case: Museum Exhibit Revisits Unsolved Murder

Whoever thought sleuthing around organized crime’s dark corridors would land you inside Las Vegas' Mob Museum, tracing the cold case trail of none other than Bugsy Siegel? Yeah, the notorious mobster whose murder on June 20, 1947, has remained frozen in mystery like a stiff in cement shoes. Now, as we inch closer to the 80-year mark since Siegel was shot dead in Beverly...

Smartpress: Adobe & Canva Shape Print Design World

Adobe's Stranglehold on Professional Design Over at Smartpress, they've pulled the curtain back on just how heavily Adobe Creative Suite weighs in on the print design sector. The company's recent analysis shines a light on the staggering 66% dominance of Adobe's InDesign and Illustrator in file submissions. That's a hefty portion influencing both the quality and financial...

Peptide Therapy Rules Change: Gameday Ups the Ante

Gameday Men's Health: Leading the Safe Peptide Charge Finally, we got some regulatory sanity stepping up to the plate with peptides. You see, the FDA's new interim policy is letting state-licensed compounding pharmacies work their magic with peptides, but only under strict medical watch. And Gameday Men's Health sure ain't wasting any time setting up shop in this fresh...

A.O. Smith Sells 81% of China Arm to CPE: Key Takeaways

When a major player like A.O. Smith decides to offload a piece of its business, folks tend to sit up and pay attention. This isn't just some run-of-the-mill shuffling. A.O. Smith has inked a deal with CPE to hand over an 81% stake in its China business. What does this transaction bring to the table and who stands to gain? Broken Down for the Curious Investor The numbers...

transcosmos: Not Just Calls—Evolving Business Strategy

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Travelers Juggle Cash and Cards Abroad: Survey Insights

Travel Spending: Balancing Convenience with Costs Navigating the financial landscape when you're a traveler abroad ain't always a walk in the park, folks. A fresh survey by Upgraded Points takes a gritty dive into how 1,500 globe-trotters juggle cash and cards while hopping across borders. The nitty-gritty? Messy exchange rates, sneaky fees, and the dreaded declined...

Chip Earnings Fuel Market Gains Amid Volatility Dip

Tech Earnings Drive Market Resilience Amid a climate of economic uncertainty, it's refreshing to see semiconductor and tech earnings offering a little backbone to the market. This week, the S&P 500 climbed 1.51%, while the Nasdaq Composite jumped 1.98% over three sessions. It's like watching Rocky get up off the mat—those indices pushing higher when it seemed like they...